Individuals with obesity have been shown to have a greater glycaemic reduction on thiazolidinediones (TZD), compared with individuals without obesity, whereas a higher BMI is associated with a smaller glycaemic reduction on DPP4-inhibitors (DPP4i)8,9. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.